Moleculin Biotech completes Part A enrollment in MIRACLE Phase 2/3 trial for relapsed/refractory AML

Moleculin Biotech said it has closed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory AML; Part A enrolled 89 patients and a comprehensive data readout is planned for Q1 2027.